Recent News and Articles on the Keywords: rimonabant + 605 + web  Related to the article below (Last Update: 8/7/2008)

This little drug went to market Sydney Morning Herald, Australia - Jul 30, 2008 The drug, Rimonabant, is a cannabis-receptor antagonist marketed in Australia as the weight loss drug Accomplia. It blocks the receptors in the brain where ... Rimonabant and Progression of Atherosclerosis in Obese Persons Journal of American Medical Association (subscription), IL - Jul 15, 2008 To the Editor: In the STRADIVARIUS trial, Dr Nissen and colleagues 1 studied the effect of rimonabant on progression of atherosclerosis in patients with ... Rimonabant and Progression of Atherosclerosis in Obese Persons?Reply Journal of American Medical Association (subscription) all 2 news articles » Cannabis compound clue to colon cancer New Scientist (subscription), UK - The research also casts a shadow on the weight-loss drug rimonabant. The drug suppresses appetite by blocking CB1, which is involved in hunger as well as ... MIMS Summary: NICE approves Acomplia Healthcare Republic (press release), UK - Jul 29, 2008 NICE has issued final guidance on the use of rimonabant (Acomplia) for the treatment of obesity. Rimonabant is recommended as an adjunct to diet and ... Supersized Problems Financial Times, UK - Jul 19, 2008 Rimonabant, known by the brand name Acomplia, joins orlistat (Xenical) and sibutramine (Reductil) in the range of weight-loss drugs available from doctors ... A Practical "ABCDE" Approach to the Metabolic Syndrome RedOrbit, TX - Aug 5, 2008 In the Rimonabant In Obesity (RIO) trials, rimonabant was shown to improve cardiovascular risk factors.106 In the Strategy to Reduce Atherosclerosis ... Sanofi diabetes drug gets European approval Hays Pharma, UK - Jul 24, 2008 The company last month said the results of a clinical trial had shown its drug rimonabant had significantly improved glucose control in type-two diabetes ...BIT:SANF - SNY Turned-off cannabinoid receptor turns on colorectal tumor growth Hindu, India - Aug 3, 2008 A CB1 antagonist called rimonabant is currently marketed overseas for weight loss. The researchers note that a patient's risk for colorectal cancer should ... Sanofi-aventis News PR Newswire (press release), NY - Jul 31, 2008 Positive results from ARPEGGIO, the first clinical trial on the administration of rimonabant to patients with type 2 diabetes not adequately controlled with ...SNY Ortho SuperSite Obesity: An increasing problem for orthopedists Ortho SuperSite, NJ - Aug 5, 2008 Rimonabant (approved in Europe only) is a CB1 receptor blocker, and works as an appetite suppressant. Side effects occur in 6% of patients treated and ...

Rimonabant shows modest benefit in reducing weight, improving HDL, triglyceride levels

Use of the weight-loss medication Rimonabant ( Acomplia ) produced modest yet sustained weight loss after 2 years, and improved HDL cholesterol and triglyceride levels.

Approximately two-thirds of U.S. adults are overweight or obese, which greatly increases the risk of developing diabetes mellitus and cardiovascular disease and death from related causes.

Researchers believe that besides weight loss, obesity management should target improvement in certain cardiometabolic risk factors, which include abnormal cholesterol and glucose levels and excess weight around the waist, according to background information in the article.
Long-term weight management remains a challenge for patients and clinicians.

F. Xavier Pi-Sunyer, of St. Luke's-Roosevelt Hospital Center, Columbia University College of Physicians and Surgeons, New York, and colleagues evaluated the efficacy and safety of the weight-loss medication Rimonabant in conjunction with diet and exercise in promoting reductions in body weight and waist circumference, long-term weight maintenance, and reduction of cardiometabolic risk factors in obese and higher risk overweight patients.

The randomized, double-blind, placebo-controlled study, conducted from August 2001 to April 2004, included 3,045 adults who were obese ( body mass index 30 or greater ) or overweight ( body mass index greater than 27 and treated or untreated hypertension or dyslipidemia ) were randomized to receive placebo, 5 mg/d of Rimonabant, or 20 mg/d of Rimonabant for 1 year.
Rimonabant-treated patients were re-randomized to receive placebo or continued to receive the same Rimonabant dose while the placebo group continued to receive placebo during year 2.

Year 1 of the study was completed by 51 percent of patients in the placebo group, 51 percent in the 5 mg of Rimonabant group, and 55 percent in the 20 mg of Rimonabant group.

After randomization, weight loss from baseline to 1-year was significantly greater in patients receiving 20 mg or 5 mg of Rimonabant than in patients receiving placebo.
The percentage of patients achieving a 5 percent or greater weight loss at 1-year was 26.1 percent for patients receiving 5 mg of Rimonabant, 48.6 percent for patients receiving 20 mg of Rimonabant, and 20.0 percent for patients receiving placebo.
Compared with the placebo group, the 20 mg of Rimonabant group produced greater average reductions in weight, waist circumference, and level of triglycerides and a greater increase in level of high-density lipoprotein ( HDL ) cholesterol.

Patients who were switched from the 20 mg of Rimonabant group to the placebo group during year 2 experienced weight regain while those who continued to receive 20 mg of Rimonabant maintained their weight loss and favorable changes in cardiometabolic risk factors.

Rimonabant was generally well tolerated; the most common drug-related adverse event was nausea ( 11.2 percent for the 20 mg of Rimonabant group vs. 5.8 percent for the placebo group ).

" It must be acknowledged that the trial was limited by a high dropout rate and that long-term effects of the drug require further study. Still, our observations collectively suggest that Rimonabant may well represent an innovative approach to the management of multiple cardiometabolic risk factors, facilitating and maintaining improvements through weight loss–dependent and –independent pathways," the authors conclude.

Source: American Medical Association, 2006